EP Patent

EP4314292A1 — Tmem173 sarna compositions and methods of use

Assigned to Mina Therapeutics Ltd · Expires 2024-02-07 · 2y expired

What this patent protects

The disclosure relates to a saRNAs useful in upregulating the expression of a target gene and therapeutic compositions comprising the saRNA, wherein the target gene is TMEM173. Methods of using the saRNA and the therapeutic compositions are also provided.

USPTO Abstract

The disclosure relates to a saRNAs useful in upregulating the expression of a target gene and therapeutic compositions comprising the saRNA, wherein the target gene is TMEM173. Methods of using the saRNA and the therapeutic compositions are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP4314292A1
Jurisdiction
EP
Classification
—
Expires
2024-02-07
Drug substance claim
No
Drug product claim
No
Assignee
Mina Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.